TY - JOUR
T1 - Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
AU - Tefferi, Ayalew
AU - Mesa, Ruben A.
AU - Gray, Leigh A.
AU - Steensma, David P.
AU - Camoriano, John K.
AU - Elliott, Michelle A.
AU - Pardanani, Animesh
AU - Ansell, Stephen M.
AU - Call, Timothy G.
AU - Colon-Otero, Gerardo
AU - Schroeder, Georgene
AU - Hanson, Curtis A.
AU - Dewald, Gordon W.
AU - Kaufmann, Scott H.
PY - 2002/5/15
Y1 - 2002/5/15
N2 - In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d. Treatment was held in 16 patients (70%), after 1 to 12 weeks, because of side effects (neutropenia, 6 patients; musculoskeletal pain, 5 patients; thrombocytosis, 4 patients; edema, 3 patients; diarrhea and hyperbilirubinemia, 1 patient). Including patients in whom retreatment at a reduced dose was possible, 11 patients (48%) were able to continue treatment beyond 3 months. None of the patients experienced a response in anemia, and only 2 had partial responses in splenomegaly. A greater than 50% increase in platelet count was documented in 11 (48%) patients, but not in those with baseline platelet counts of less than 100 × 109/L. In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit.
AB - In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d. Treatment was held in 16 patients (70%), after 1 to 12 weeks, because of side effects (neutropenia, 6 patients; musculoskeletal pain, 5 patients; thrombocytosis, 4 patients; edema, 3 patients; diarrhea and hyperbilirubinemia, 1 patient). Including patients in whom retreatment at a reduced dose was possible, 11 patients (48%) were able to continue treatment beyond 3 months. None of the patients experienced a response in anemia, and only 2 had partial responses in splenomegaly. A greater than 50% increase in platelet count was documented in 11 (48%) patients, but not in those with baseline platelet counts of less than 100 × 109/L. In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit.
UR - http://www.scopus.com/inward/record.url?scp=0037093060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037093060&partnerID=8YFLogxK
U2 - 10.1182/blood-2001-12-0154
DO - 10.1182/blood-2001-12-0154
M3 - Article
C2 - 11986248
AN - SCOPUS:0037093060
SN - 0006-4971
VL - 99
SP - 3854
EP - 3856
JO - Blood
JF - Blood
IS - 10
ER -